Expression of multidrug resistance-associated proteins in rhabdomyosarcomas before and after chemotherapy: The relationship between lung resistance-related protein (LRP) and differentiation

Human Pathology

Volumn 34, Issue 2, 2003, Pages 150-155

  Klunder, J W ^a   Komdeur, R ^a   Van Der Graaf, W T A ^a   De Bont, E J S M ^a   Hoekstra, H J ^a   Van Den Berg, E ^a   Molenaar, Willemina M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Differentiation; Lung resistance related protein; Multidrug resistance associated proteins; Rhabdomyosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IFOSFAMIDE; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PROTEIN EXPRESSION; RHABDOMYOSARCOMA;

EID: 0037327923     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2003.10     Document Type: Article

References (35)

1. La Quaglia MP, Heller G, Ghavimi F, et al: The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer 73:109-117, 1994
2. Pappo AS, Shapiro DN, Crist WM, et al: Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 13:2123-2139, 1995
3. Crist W, Gehan EA, Ragab AH, et al: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13:610-630, 1995
4. Molenaar WM, Oosterhuis JW, Kamps WA: Cytologic "differentiation" in childhood rhabdomyosarcomas following polychemotherapy. HUM PATHOL 15:973-979, 1984
5. Coffin CM, Rulon J, Smith L, et al: Pathologic features of rhabdomyosarcoma before and after treatment: A clinicopathologic and immunohistochemical analysis. Mod Pathol 10:1175-1187, 1997
6. d'Amore ES, Tollot M, Stracca-Pansa V, et al: Therapy-associated differentiation in rhabdomyosarcomas. Mod Pathol 7:69-75, 1994
7. Leuschner I, Harms D, Mattke A, et al: Rhabdomyosarcoma of the urinary bladder and vagina: A clinicopathologic study with emphasis on recurrent disease. A report from the Kiel Pediatric Tumor Registry and the German CWS Study. Am J Surg Pathol 25:856-864, 2001
8. Molenaar WM, Oosterhuis JW, Oosterhuis AM, et al: Mesenchymal and muscle-specific intermediate filaments (vimentin and desmin) in relation to differentiation in childhood rhabdomyosarcomas. HUM PATHOL 16:838-843, 1985
9. Lollini PL, De Giovanni C, del Re B, et al: Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs. Cancer Res 49:3631-3636, 1989
10. Marchal JA, Prados J, Melguizo C, et al: GR-891: A novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells. Br J Cancer 79:807-813, 1999
11. Melguizo C, Prados J, Marchal JA, et al: Low concentrations of actinomycin D potentially cause therapeutic differentiation in human rhabdomyosarcoma cell line RD. Pathol Res Pract 192:188-194, 1996
12. Melguizo C, Prados J, Velez C, et al: Influence of dimethyl sulphoxide on intermediate filament proteins in human rhabdomyosarcoma cell lines: Modulation at a subcellular level. Histochem J 26:519-525, 1994
13. Marchal JA, Prados J, Melguizo C, et al: Actinomycin D treatment leads to differentiation and inhibits proliferation in rhabdomyosarcoma cells. J Lab Clin Med 130:42-50, 1997
14. Chaudhary PM, Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85:632-639, 1993
15. Colvin OM: Drug resistance in the treatment of sarcomas. Semin Oncol 24:580-591, 1997
16. Dalton WS, Scheper RJ: Lung resistance-related protein: Determining its role in multidrug resistance. J Natl Cancer Inst 91:1604-1605, 1999
17. Nooter K, Westerman AM, Flens MJ, et al: Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1:1301-1310, 1995
18. Izquierdo MA, Scheffer GL, Flens MJ, et al: Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 148:877-887, 1996
19. Scheffer GL, Schroeijers AB, Izquierdo MA, et al: Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12:550-556, 2000
20. Scheper RJ, Broxterman HJ, Scheffer GL, et al: Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475-1479, 1993
21. Colvin OM: Mechanisms of resistance to alkylating agents. Cancer Treat Res 73:249-262, 1994
22. Weiss SW, Goldblum JR: Enzinger and Weiss' Soft Tissue Tumors (ed 4). St Louis, MO, Mosby, 2001
23. Abolhoda A, Wilson AE, Ross H, et al: Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5:3352-3356, 1999
24. Fojo AT, Ueda K, Slamon DJ, et al: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84:265-269, 1987
25. Jimenez RE, Zalupski MM, Frank JJ, et al: Multidrug resistance phenotype in high-grade soft tissue sarcoma: Correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer 86:976-981, 1999
26. Prados J, Melguizo C, Marchal JA, et al: Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D. Int J Cancer 75:379-383, 1998
27. Komdeur R, Plaat BE, Hoekstra HJ, et al: Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer 91:1940-1948, 2001
28. Grogan TM, Spier CM, Salmon SE, et al: P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood 81:490-495, 1993
29. Schneider E, Cowan KH, Bader H, et al: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186-193, 1995
30. van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, et al: MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 97:3605-3611, 2001
31. List AF, Spier CS, Grogan TM, et al: Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87:2464-2469, 1996
32. Schroeijers AB, Reurs AW, Scheffer GL, et al: Up-regulation of drug resistance-related vaults during dendritic cell development. J Immunol 168:1572-1578, 2002
33. Kitazono M, Sumizawa T, Takebayashi Y, et al: Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91:1647-1653, 1999
34. Kitazono M, Okumura H, Ikeda R, et al: Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int J Cancer 91:126-131, 2001
35. Crouch GD, Kalebic T, Tsokos M, et al: Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell line. Exp Cell Res 204:210-216, 1993